165 related articles for article (PubMed ID: 22735832)
1. Carbohydrate antigen 125: a new biomarker in heart failure.
Vizzardi E; D'Aloia A; Curnis A; Dei Cas L
Cardiol Rev; 2013; 21(1):23-6. PubMed ID: 22735832
[TBL] [Abstract][Full Text] [Related]
2. Tumour biomarkers in heart failure: is there a role for CA-125?
Yilmaz MB; Nikolaou M; Cohen Solal A
Eur J Heart Fail; 2011 Jun; 13(6):579-83. PubMed ID: 21525015
[TBL] [Abstract][Full Text] [Related]
3. Tumour markers in chronic heart failure. Review of the literature and clinical implications.
Faggiano P; D'Aloia A; Antonini-Canterin F; Vizzardi E; Nicolosi GL; Cas LD
J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):573-9. PubMed ID: 16858234
[TBL] [Abstract][Full Text] [Related]
4. [CA-125 - does this next biomarker have a chance to hope for an expectation of risk stratification in patients with heart failure?].
Zieliński T
Kardiol Pol; 2010 Jul; 68(7):779-80. PubMed ID: 20648435
[No Abstract] [Full Text] [Related]
5. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women.
Hung CL; Hung TC; Liu CC; Wu YJ; Kuo JY; Hou CJ; Yeh HI
Am J Cardiol; 2012 Oct; 110(7):993-1000. PubMed ID: 22728006
[TBL] [Abstract][Full Text] [Related]
6. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure.
Núñez J; Sanchis J; Bodí V; Fonarow GC; Núñez E; Bertomeu-González V; Miñana G; Consuegra L; Bosch MJ; Carratalá A; Chorro FJ; Llàcer A
Eur Heart J; 2010 Jul; 31(14):1752-63. PubMed ID: 20501480
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pleural effusion, CA-125 and NT-proBNP in patients with acute decompensated heart failure.
Davutoglu V; Yildirim C; Kucukaslan H; Yuce M; Sari I; Tarakcioglu M; Akcay M; Cakici M; Ceylan N; Al B
Kardiol Pol; 2010 Jul; 68(7):771-8. PubMed ID: 20648434
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
[TBL] [Abstract][Full Text] [Related]
9. [Use of brain natriuretic peptide (BNP) in the diagnosis and treatment of heart failure].
Martin-Du Pan RC; Ricou F
Rev Med Suisse Romande; 2003 Feb; 123(2):125-8. PubMed ID: 15095695
[TBL] [Abstract][Full Text] [Related]
10. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies.
Zhuang J; Faggiano P; Li Q; Pradelli D; Med V; Peng W; Zuo M; Xu Y
J Cardiovasc Med (Hagerstown); 2014 Dec; 15(12):864-72. PubMed ID: 25353973
[TBL] [Abstract][Full Text] [Related]
11. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume.
Duman D; Palit F; Simsek E; Bilgehan K
Eur J Heart Fail; 2008 Jun; 10(6):556-9. PubMed ID: 18501671
[TBL] [Abstract][Full Text] [Related]
12. Brain natriuretic peptide in heart failure and beyond.
Mowla MM; Bustami BB
Saudi Med J; 2006 Oct; 27(10):1457-61. PubMed ID: 17013463
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in heart failure management.
Isaac DL
Curr Opin Cardiol; 2008 Mar; 23(2):127-33. PubMed ID: 18303525
[TBL] [Abstract][Full Text] [Related]
14. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement.
Antonini-Canterin F; Popescu BA; Popescu AC; Beladan CC; Korcova R; Piazza R; Cappelletti P; Rubin D; Cassin M; Faggiano P; Nicolosi GL
Int J Cardiol; 2008 Aug; 128(3):406-12. PubMed ID: 17662495
[TBL] [Abstract][Full Text] [Related]
15. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure.
Bettencourt P; Januzzi JL
Am J Cardiol; 2008 Feb; 101(3A):67-71. PubMed ID: 18243862
[TBL] [Abstract][Full Text] [Related]
16. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.
Wu AH
Am Heart J; 2006 Nov; 152(5):828-34. PubMed ID: 17070141
[TBL] [Abstract][Full Text] [Related]
17. [Clinical utility of NT-proBNP, a new biomarker of cardiac function and heart failure].
Ishii J
Rinsho Byori; 2008 Apr; 56(4):316-21. PubMed ID: 18516966
[TBL] [Abstract][Full Text] [Related]
18. Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients.
Vizzardi E; D'Aloia A; Pezzali N; Bugatti S; Curnis A; Dei Cas L
J Card Fail; 2012 Jan; 18(1):68-73. PubMed ID: 22196844
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management.
Palazzuoli A; Caputo M; Calabrò A; Nuti R
Minerva Cardioangiol; 2012 Apr; 60(2):183-94. PubMed ID: 22495167
[TBL] [Abstract][Full Text] [Related]
20. Updating the role of natriuretic peptide levels in cardiovascular disease.
Gopal DJ; Iqbal MN; Maisel A
Postgrad Med; 2011 Nov; 123(6):102-13. PubMed ID: 22104459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
